These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 11777752

  • 1. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
    Stockis A, De Bruyn S, Deroubaix X, Jeanbaptiste B, Lebacq E, Nollevaux F, Poli G, Acerbi D.
    Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752
    [Abstract] [Full Text] [Related]

  • 2. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
    Vree TB, Dammers E, Valducci R.
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
    [Abstract] [Full Text] [Related]

  • 3. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
    Sata H, Inoue K, Nii T, Kuroda T.
    Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
    Niopas I, Daftsios AC, Nikolaidis N.
    Int J Clin Pharmacol Ther; 2001 May; 39(5):224-8. PubMed ID: 11380069
    [Abstract] [Full Text] [Related]

  • 7. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
    Zhang Q, Huang X, Ji P, Fu L, Yan B, Wei S.
    Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
    [Abstract] [Full Text] [Related]

  • 8. A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers.
    Storm G, Oosterhuis B, Bron J, Wittebrood AJ, De Jong AP, Jonkman JH.
    Biopharm Drug Dispos; 1991 Dec; 12(9):661-72. PubMed ID: 1790311
    [Abstract] [Full Text] [Related]

  • 9. Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form.
    Jähnchen E.
    Br J Clin Pharmacol; 1992 Dec; 34 Suppl 1(Suppl 1):15S-17S. PubMed ID: 1633073
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
    Darwish M, Yang R, Tracewell W, Robertson P, Bond M.
    Clin Ther; 2015 Feb 01; 37(2):390-401. PubMed ID: 25542074
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies.
    Jenner P, Könen-Bergmann M, Schepers C, Haertter S.
    Clin Ther; 2009 Nov 01; 31(11):2698-711. PubMed ID: 20110012
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C, Bujanover S, Kareht S, Rapoport AM.
    Headache; 2015 Feb 01; 55(2):265-75. PubMed ID: 25546369
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetics of hydrocodone extended-release tablets formulated with different levels of coating to achieve abuse deterrence compared with a hydrocodone immediate-release/acetaminophen tablet in healthy subjects.
    Darwish M, Bond M, Tracewell W, Robertson P, Yang R.
    Clin Drug Investig; 2015 Jan 01; 35(1):13-22. PubMed ID: 25391549
    [Abstract] [Full Text] [Related]

  • 17. Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
    Vaidyanathan S, Bartlett M, Dieterich HA, Yeh CM, Antunes A, Howard D, Dole WP.
    Cardiovasc Ther; 2008 Jan 01; 26(4):238-46. PubMed ID: 19035874
    [Abstract] [Full Text] [Related]

  • 18. Development of monolithic osmotic pump tablet system for isosorbide-5-mononitrate delivery and evaluation of it in vitro and in vivo.
    Duan X, Liu Q, Zhang Y, Bi K, Chen X, Wang Y, Luo G.
    Drug Dev Ind Pharm; 2009 Apr 01; 35(4):499-507. PubMed ID: 18979308
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of isosorbide mononitrate.
    Abshagen UW.
    Am J Cardiol; 1992 Nov 27; 70(17):61G-66G. PubMed ID: 1449102
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
    Chrysant SG, Glasser SP, Bittar N, Shahidi FE, Danisa K, Ibrahim R, Watts LE, Garutti RJ, Ferraresi R, Casareto R.
    Am J Cardiol; 1993 Dec 01; 72(17):1249-56. PubMed ID: 8256699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.